Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000355348

Medchemexpress LLC BLU-945 | 2660250-10-0 | 99.4% | C28H37FN6O3S | 100 MG
SDP

Catalog No. 5000355348
Encompass_Preferred

BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation, making it suitable for research into lung cancer, including non-small cell lung cancer (NSCLC).

  • Potent, highly selective, reversible, and orally active EGFR tyrosine kinase inhibitor.
  • Effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation.
  • Used for research of lung cancer, including non-small cell lung cancer (NSCLC).
  • Exhibits inhibitory activity against EGFRm/T790M double and EGFRm/T790M/C797S triple mutants.
  • Demonstrates potent, robust EGFR pathway inhibition and anti-tumor activity in Osimertinib-resistant models.

Catalog No. 50-003-55348 Supplier Medchemexpress LLC Supplier No. HY144680100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation, making it suitable for research into lung cancer, including non-small cell lung cancer (NSCLC).

  • Potent, highly selective, reversible, and orally active EGFR tyrosine kinase inhibitor.
  • Effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation.
  • Used for research of lung cancer, including non-small cell lung cancer (NSCLC).
  • Exhibits inhibitory activity against EGFRm/T790M double and EGFRm/T790M/C797S triple mutants.
  • Demonstrates potent, robust EGFR pathway inhibition and anti-tumor activity in Osimertinib-resistant models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.